Literature DB >> 25349299

Anti-vascular endothelial growth factor therapy in breast cancer: game over?

George W Sledge1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25349299     DOI： 10.1200/JCO.2014.58.1298

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  18 in total

Review 1.  Advancing Immunotherapy in Metastatic Breast Cancer.

Authors:  Mariam Mansour; Zhi Ling Teo; Stephen J Luen; Sherene Loi
Journal:  Curr Treat Options Oncol       Date:  2017-06

2.  [Agkistrodon halys venom antitumor component-I inhibits vasculogenic mimicry in triple-negative breast cancer cells in vitro by down-regulating MMP2].

Authors:  Y Ge; L Lu; S Tian; Y Xiao; S Xie; Q Wang; H Zhi
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-03-20

Review 3.  Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity.

Authors:  John D Martin; Dai Fukumura; Dan G Duda; Yves Boucher; Rakesh K Jain
Journal:  Cold Spring Harb Perspect Med       Date:  2016-12-01       Impact factor: 6.915

4.  Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients.

Authors:  Sara M Tolaney; Yves Boucher; Dan G Duda; John D Martin; Giorgio Seano; Marek Ancukiewicz; William T Barry; Shom Goel; Johanna Lahdenrata; Steven J Isakoff; Eren D Yeh; Saloni R Jain; Mehra Golshan; Jane Brock; Matija Snuderl; Eric P Winer; Ian E Krop; Rakesh K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-02       Impact factor: 11.205

Review 5.  Emerging therapeutic targets in metastatic progression: A focus on breast cancer.

Authors:  Zhuo Li; Yibin Kang
Journal:  Pharmacol Ther       Date:  2016-03-19       Impact factor: 12.310

Review 6.  Targeting metastasis.

Authors:  Patricia S Steeg
Journal:  Nat Rev Cancer       Date:  2016-04       Impact factor: 60.716

Review 7.  Anti-vascular endothelial growth factor therapy in breast cancer.

Authors:  Tina Bøgelund Kristensen; Malin L T Knutsson; Markus Wehland; Britt Elmedal Laursen; Daniela Grimm; Elisabeth Warnke; Nils E Magnusson
Journal:  Int J Mol Sci       Date:  2014-12-11       Impact factor: 5.923

8.  VEGFR2 targeted antibody fused with MICA stimulates NKG2D mediated immunosurveillance and exhibits potent anti-tumor activity against breast cancer.

Authors:  Wei Xie; Fang Liu; Youfu Wang; Xueyan Ren; Tong Wang; Zhiguo Chen; Mingying Tang; Fumou Sun; Zhaoting Li; Min Wang; Juan Zhang
Journal:  Oncotarget       Date:  2016-03-29

Review 9.  MDA-9/Syntenin (SDCBP): Novel gene and therapeutic target for cancer metastasis.

Authors:  Swadesh K Das; Santanu Maji; Stephen L Wechman; Praveen Bhoopathi; Anjan K Pradhan; Sarmistha Talukdar; Devanand Sarkar; Joseph Landry; Chunqing Guo; Xiang-Yang Wang; Webster K Cavenee; Luni Emdad; Paul B Fisher
Journal:  Pharmacol Res       Date:  2020-02-13       Impact factor: 7.658

10.  Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer.

Authors:  Teresa Di Desidero; Ping Xu; Shan Man; Guido Bocci; Robert S Kerbel
Journal:  Oncotarget       Date:  2015-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.